跳轉至內容
Merck
全部照片(3)

文件

O7125

Sigma-Aldrich

L-鸟氨酸 L-天冬氨酸盐

≥98% (TLC)

同義詞:

(S)-2,5-二氨基戊酸 L-天冬氨酸盐

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C9H19N3O6
CAS號碼:
分子量::
265.26
EC號碼:
MDL號碼:
分類程式碼代碼:
12352209
PubChem物質ID:
NACRES:
NA.26

product name

L-鸟氨酸 L-天冬氨酸盐, powder

化驗

≥98% (TLC)

形狀

powder

顏色

white to off-white

儲存溫度

2-8°C

SMILES 字串

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

InChI

1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

InChI 密鑰

IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

尋找類似的產品? 前往 產品比較指南

生化/生理作用

L-鸟氨酸 L-天冬氨酸是精氨酸酶降解精氨酸的代谢产物。已经表明它通过增加氨来降低血氨浓度肌肉解毒,并减轻肝硬化肝性脑病的严重程度。

其他說明

精氨酸通过精氨酸酶降解所得产物

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Janus P Ong et al.
Clinical drug investigation, 31(4), 213-220 (2011-01-07)
Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The
Babette Linde et al.
Medizinische Klinik (Munich, Germany : 1983), 102(10), 846-851 (2007-10-12)
Fulminate liver insufficiency can have many causes and is a challenge for differential diagnosis. A 39-year-old woman was admitted because of a nonitching macular-papular exanthema on both thighs with spreading to the trunk. In addition, the patient complained of dysphagia
Vibhu Vibhas Mittal et al.
European journal of gastroenterology & hepatology, 23(8), 725-732 (2011-06-08)
Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Patrícia Coelho de Soárez et al.
Arquivos de gastroenterologia, 46(3), 241-247 (2009-11-18)
Experimental and clinical studies suggest that LOLA may have a favorable influence on hepatic encephalopathy due to the effect on the reduction of ammonia, and improvement of the symptoms and laboratory findings. To evaluate and to critically analyze the efficacy

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務